Product information and disease description Product description Product information

Average sales price and wholesale acquisition cost

4 evidence topics · 2 sources

United States: wholesale acquisition cost by package

Package	NDC	WAC price
Tablets, 16 count	“82950-0001-16”	“$35,272.64”
Oral suspension, 1 bottle	“82950-0012-01”	“$8,818.16”

United States: wholesale acquisition cost disclosure terms

“OJEMDA 100 MG TABLET (20 tablets)” (opens the source at this quote in a new tab)
“OJEMDA for oral suspension (1 single use bottle, 7-day supply, 4 bottles for 28-day supply)” (opens the source at this quote in a new tab)
“Data as of: 01/01/2025” (opens the source at this quote in a new tab)
“WAC does not reflect discounts, rebates and other reductions in price.” (opens the source at this quote in a new tab)

United States: annual launch list price and estimated net price

Drug	Annual list price	Best annual net price estimate
Ojemda (tovorafenib)	“$330,720.00”	“$297,648.00”

United States: dose assumption for the annual price estimate

“We used the 375 mg weekly dose in our calculations.” (opens the source at this quote in a new tab)

United States: average sales price

Not applicable.

Prices outside the United States

No evidence found.